RxDoctor Payments Data

Brittney Sivils

Family · Fort Smith, ARNPI 1447590864

Payments from drug & device makers

$4,482in general payments, 2019–2025

Across 169 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Novartis$404
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$326
  • Novo Nordisk$301
  • E.r. Squibb & Sons, L.L.C.$288
  • Johnson & Johnson$198
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,13025%
  • Food & beverage$3,35275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,482 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$42,473
Medicare patients
538
Services billed
693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban57$74,792
EliquisApixaban41$39,575
EntrestoSacubitril/Valsartan13$20,594
Ranolazine ErRanolazine79$6,326
Metoprolol Succinate123$1,598
Isosorbide Dinitrate41$1,577
Amiodarone Hcl18$1,026
Bumetanide24$1,008
Hydralazine Hcl78$708
Carvedilol109$704
ClopidogrelClopidogrel Bisulfate51$614
Atorvastatin Calcium89$605
FenofibrateFenofibrate Nanocrystallized37$566
Nitroglycerin63$550
Losartan Potassium50$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$198$74,79257 claims
PfizerEliquis$58$39,57541 claims
NovartisEntresto$404$20,59413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.

Other family in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →